Peer-reviewed veterinary case report
Mirtazapine ointment helps cats gain weight after unintended loss
By Poole, Melinda et al.·Published in Journal of veterinary pharmacology and therapeutics·2019·Kindred Biosciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A double-blind, placebo-controlled, randomized study to evaluate the weight gain drug, mirtazapine transdermal ointment, in cats with unintended weight loss.
- Species:
- cat
Plain-English summary
A group of cats with unintended weight loss were treated with a weight gain drug called mirtazapine, applied as a transdermal ointment on their ears. Over two weeks, the cats receiving mirtazapine gained an average of 3.9% of their body weight, while those given a placebo only gained 0.4%. The treatment was generally well tolerated, with only a few cats experiencing mild skin irritation at the application site. This suggests that mirtazapine can be an effective option for helping cats regain weight when they have lost it due to various health issues.
People also search for: cat weight loss treatment · mirtazapine for cats · how to help my cat gain weight
Abstract
Mirtazapine is classified as a weight gain drug in cats, and the purpose of this study was to evaluate its efficacy in cats experiencing unintended weight loss. This was a multi-center, double-blind, placebo-controlled, randomized clinical study in client-owned cats ≥1 year of age, weighing ≥2 kg, with a documented loss (≥5%) in body weight. Cats were treated once daily with either 2 mg/cat mirtazapine transdermal ointment (n = 83) or placebo (n = 94) (Per Protocol population) applied to the inner surface of the pinna for 14 ± 3 days. Physical examination, body weight, complete blood count, serum chemistry, and urinalysis were performed prior to treatment and on Day 14. Changes in body weight between the mirtazapine and placebo groups were evaluated from Day 1 to Day 14 and compared using a two-sample t test. The mean percent change in body weight was +3.9% (standard deviation ±5.4%) in the mirtazapine group and +0.4% (±3.3%) in the placebo group (p < 0.0001). The most common adverse event was mild erythema at the application site in 17.4% of placebo and 10.4% of mirtazapine-treated cats. Application of mirtazapine transdermal ointment was well tolerated both topically and systemically and resulted in significant weight gain in cats experiencing unintended weight loss associated with various underlying diseases.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/30506924/